Washington University School of Medicine

Digital Commons@Becker
2020-Current year OA Pubs

Open Access Publications

6-21-2022

Fine-tuning cardiac insulin-like growth factor 1 receptor signaling
to promote health and longevity
Mahmoud Abdellatif
Medical University of Graz

Tobias Pendl
Washington University School of Medicine in St. Louis

Sebastian J Hofer
Washington University School of Medicine in St. Louis

Moydul Islam
Washington University School of Medicine in St. Louis

Abhinav Diwan
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4
Part of the Medicine and Health Sciences Commons

Recommended Citation
Abdellatif, Mahmoud; Pendl, Tobias; Hofer, Sebastian J; Islam, Moydul; Diwan, Abhinav; Eisenberg, Tobias;
Madeo, Frank; and et al, "Fine-tuning cardiac insulin-like growth factor 1 receptor signaling to promote
health and longevity." Circulation. 145, 25. 1853 - 1866. (2022).
https://digitalcommons.wustl.edu/oa_4/200

This Open Access Publication is brought to you for free and open access by the Open Access Publications at
Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized
administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors
Mahmoud Abdellatif, Tobias Pendl, Sebastian J Hofer, Moydul Islam, Abhinav Diwan, Tobias Eisenberg,
Frank Madeo, and et al

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/oa_4/200

Circulation
ORIGINAL RESEARCH ARTICLE

Fine-Tuning Cardiac Insulin-Like Growth
Factor 1 Receptor Signaling to Promote
Health and Longevity
Mahmoud Abdellatif , MD, PhD; Viktoria Trummer-Herbst, MSc; Alexander Martin Heberle , PhD; Alina Humnig, MSc;
Tobias Pendl, PhD; Sylvère Durand, PhD; Giulia Cerrato , PhD; Sebastian J. Hofer , PhD; Moydul Islam , MSc;
Julia Voglhuber , MSc; José Miguel Ramos Pittol , PhD; Oliver Kepp , PhD; Gerald Hoefler, MD; Albrecht Schmidt, MD;
Peter P. Rainer , MD, PhD; Daniel Scherr, MD; Dirk von Lewinski, MD; Egbert Bisping , MD; Julie R. McMullen, PhD;
Abhinav Diwan, MD; Tobias Eisenberg , PhD; Frank Madeo, PhD; Kathrin Thedieck , PhD; Guido Kroemer , MD, PhD;
Simon Sedej , PhD
BACKGROUND: The insulin-like growth factor 1 (IGF1) pathway is a key regulator of cellular metabolism and aging. Although its
inhibition promotes longevity across species, the effect of attenuated IGF1 signaling on cardiac aging remains controversial.
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METHODS: We performed a lifelong study to assess cardiac health and lifespan in 2 cardiomyocyte-specific transgenic mouse
models with enhanced versus reduced IGF1 receptor (IGF1R) signaling. Male mice with human IGF1R overexpression
or dominant negative phosphoinositide 3-kinase mutation were examined at different life stages by echocardiography,
invasive hemodynamics, and treadmill coupled to indirect calorimetry. In vitro assays included cardiac histology, mitochondrial
respiration, ATP synthesis, autophagic flux, and targeted metabolome profiling, and immunoblots of key IGF1R downstream
targets in mouse and human explanted failing and nonfailing hearts, as well.
RESULTS: Young mice with increased IGF1R signaling exhibited superior cardiac function that progressively declined
with aging in an accelerated fashion compared with wild-type animals, resulting in heart failure and a reduced lifespan.
In contrast, mice with low cardiac IGF1R signaling exhibited inferior cardiac function early in life, but superior cardiac
performance during aging, and increased maximum lifespan, as well. Mechanistically, the late-life detrimental effects
of IGF1R activation correlated with suppressed autophagic flux and impaired oxidative phosphorylation in the heart.
Low IGF1R activity consistently improved myocardial bioenergetics and function of the aging heart in an autophagydependent manner. In humans, failing hearts, but not those with compensated hypertrophy, displayed exaggerated
IGF1R expression and signaling activity.
CONCLUSIONS: Our findings indicate that the relationship between IGF1R signaling and cardiac health is not linear, but rather
biphasic. Hence, pharmacological inhibitors of the IGF1 pathway, albeit unsuitable for young individuals, might be worth
considering in older adults.
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Biphasic Effects of Cardiac IGF1R Signaling

Clinical Perspective
What Is New?
• End-stage failing human hearts, but not those with
compensated hypertrophy, display exaggerated
insulin/insulin-like growth factor 1 receptor (IGF1R)
expression and signaling activity.
• Cardiomyocyte IGF1R overexpression in mice
results in physiological hypertrophy and superior
cardiac function in early life, but leads to accelerated cardiac aging, heart failure, and reduced lifespan in late life.
• Increased cardiomyocyte IGF1R signaling accentuates cardiac dysfunction by reducing autophagy
and mitochondrial oxidative capacity at old age.

What Are the Clinical Implications?
• Pharmacological inhibition of cardiac IGF1R signaling in late life could suppress the age-related
deterioration of cardiac performance and increase
lifespan.
• Age should be considered as a major outcome
determinant in future clinical trials testing IGF1R/
phosphoinositide 3-kinase inhibitors for cardiac
benefits.
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Nonstandard Abbreviations and Acronyms
4E-BP1 eIF4E-binding protein 1
dnPI3K	mice harboring an inactivated (dominant
negative, dn) p110α isoform of PI3K
EF
ejection fraction
HCQ
hydroxychloroquine
IGF1
insulin-like growth factor 1
IGF1Rtg	mice overexpressing the human IGF1R
specifically in cardiac myocytes
LC3B-II	autophagy-related lipidated form of
microtubule-associated protein 1A/1Blight chain 3B
LV
left ventricle
mTORC1	mammalian target of rapamycin complex 1
p70 S6K p70 ribosomal S6 kinase 1
PI3K
phosphoinositide 3-kinase
PRAS40 proline-rich AKT1 substrate 1
ULK-1
unc-51-like kinase-1

T

he insulin-like growth factor 1 (IGF1) pathway is
a master regulator of cellular metabolism, growth,
and aging.1 Previous genomic studies revealed
that loss-of-function mutations in the IGF1 receptor
(IGF1R) or its downstream effectors promote longevity
in various model organisms.2 In mammals, however, the
lifespan-extending effect appears limited to females,3,4
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and its magnitude depends on the genetic background.5
Although these research efforts have provided important
insights into the role of IGF1R signaling in the modulation of lifespan, the effect of diminished IGF1R signaling
on healthspan (ie, the disease-free period of life), with
the exception of cancer, remains largely controversial.6,7
Such uncoupling of lifespan and healthspan underscores the need to investigate whether IGF1R signaling
regulates the pace of aging in a cell-autonomous manner. That said‚ only a few animal studies have examined
the salutary effects of cell- or tissue-specific IGF1R signaling modulation throughout the course of life.8,9
In this context, IGF1R signaling is recognized to
be most critical for cardiac homeostasis.2 As such,
reduced cardiomyocyte IGF1R signaling has been
shown to exert detrimental effects, whereas its activation is linked to enhanced cardiac contractility and
physiological hypertrophy.10,11 However, recent studies reported that reduced IGF1R signaling attenuates
adverse cardiac remodeling in genuinely aged mice
(ie, >18 months old), whereas late-in-life treatment
with IGF1R monoclonal antibodies improved cardiac
function, at least in female mice.3,12 To reconcile these
disparate observations, it has been postulated that
the cardiac outcomes of IGF1R manipulation might
be beneficial or detrimental depending on whether
the heart is young or old, respectively.2 However, this
assumption remains heretofore untested, and lifelong
studies elucidating the underlying mechanisms of
such biphasic and age-dependent cardiac effect of
IGF1 are still lacking.
To address this knowledge gap, we performed a lifelong study, in which we comprehensively assessed cardiac health and lifespan of 2 transgenic mouse models
with opposing effects on IGF1R signaling in cardiomyocytes. Here, we demonstrate that the cardiac advantages
in young male mice with increased cardiomyocyte IGF1R
signaling are lost and even inverted later in life, leading to
accentuated age-related cardiac decline and heart failure. In contrast, low IGF1R signaling suppressed cardiac
growth and function in young mice but preserved cardiac
health in aging. Reduced cardiac autophagic flux and
mitochondrial oxidative capacity mechanistically underlay the late-life detrimental effects of increased IGF1R
signaling. Low IGF1R signaling consistently improved
myocardial bioenergetics and protected the heart from
age-related dysfunction in an autophagy-dependent
manner. In humans, explanted failing hearts displayed
increased IGF1R expression and pathway activity, supporting that these results may be clinically relevant.

METHODS
The data supporting the results are available within the article
and its Supplemental Material. On reasonable request, data,
analytic methods, and study materials will be made available
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Male mice overexpressing human IGF1R specifically in cardiomyocytes (IGF1Rtg mice)10 or male mice expressing a dominant
negative phosphoinositide 3-kinase (PI3K) p110α mutant with
impaired catalytic activity restricted to cardiomyocytes (dnPI3K
mice)13 were used. In brief, a truncated p110 mutant with p85
binding domains, but lacking the kinase domain (p110Δkinase),
was generated, and the p110Δkinase gene, together with FLAG
epitope tag, was cloned into the αMyHC promoter construct
to produce dnPI3K transgenic mice.13 Both transgenic mouse
models and their wild-type (WT) littermates were generated
on the FVB/N genetic background and used at 3, 6, 9, 12, or
20 months of age, and were euthanized for tissue analysis as
indicated. In a separate set of studies, spermidine (No. S2626;
Sigma-Aldrich) was administered orally (3 mmol/L in the drinking
water) to 15-month-old IGF1Rtg mice for 5 months.14 A subgroup
of dnPI3K and WT mice were assigned at the age of 19 months
to receive daily intraperitoneal injections of hydroxychloroquine
(60 mg/kg; Cayman Chemical) for 4 weeks.15 The experimenters
were blinded to the genotype and treatment of mice.
Genotype was determined from ear biopsies by polymerase
chain reaction–based analysis using the following primers: IGF1R
or dnPI3K forward: αMHC-4, 5′GGC ACT TTA CAT GGA GTC
CT3′ (Lot No.: 2355627, Microsynth); IGF1R reverse, 5′GAA CAG
CAA GTA CTC GGT AAT3′ (Lot No.: 2355628); and p110-2R
reverse, 5′TGGCCTCTCTGAACAGTTCAT3′ (Lot No.: 2355626).
Mice were housed in a temperature- and humidity-controlled animal facility under specific pathogen-free or conventional conditions in 12-hour dark/light cycles with ad libitum access to water
and food (standard chow, Ssniff V1534, ssniff-Spezialdiäten
GmbH). Because of excessive fighting, we commonly housed 1 or
2 mice per cage that was enriched with autoclaved nest material
and paper houses.
Details on mouse lifespan evaluation, echocardiography,
hemodynamics, exercise tolerance testing and indirect calorimetry, mitochondrial respiration and ATP synthesis assays,
autophagic flux assessment, immunoblotting and quantitative
polymerase chain reaction analysis, metabolites profiling, and
morphometric analysis of hypertrophy and fibrosis are in the
Supplemental Material.
All animal experiments were performed according to
the European ethical regulations (Directive 2010/63/
EU) and were approved by the responsible national agencies (Bundesministerium für Wissenschaft, Forschung und
Wirtschaft, BMWFW, Austria: BMWFW-66.010/0160-WF/
V/3b/2014, BMWFW-66.010/0198-WF/V/3b/2017, and
BMBWF-66.010/0042-V/3b/2018).

Human Samples
Myocardial samples were obtained from explanted donor
hearts. On ice-cold cardioplegia, cardiac biopsies were harvested from the left ventricular free wall, quickly frozen in liquid
nitrogen, and stored at –80 °C for future analysis. Donors of
the failing hearts had severe contractile dysfunction and underwent cardiac transplantation surgery because of end-stage
nonischemic dilated cardiomyopathy. Compensated hypertrophy samples were procured from deceased donors with

echocardiographic evidence of moderate-to-severe hypertrophic remodeling, defined as interventricular septum thickness
≥13 mm, and preserved ejection fraction (EF) ≥50%.16 The
nonfailing nonhypertrophied hearts were from donors with no
clinical history of cardiac abnormalities, and echocardiographyderived interventricular septum ≤12 mm and EF ≥50%, as well.
The human study protocol conformed to the Declaration of
Helsinki. The requirement for informed consent was waived by
the institutional ethics committee, which approved the collection and reporting of biological material and patients’ characteristics, respectively (Ethical votum No.: 24-224 ex 11/12 and
28-508 ex 15/16; Medical University of Graz).

Statistical Analysis
Data are presented as bar graphs with error bars showing mean
and SEM, respectively, along with individual data points superimposed. Indicated sample sizes in figure legends refer to biological replicates (ie, individual hearts/animals). Comparisons
between 2 groups were done by the Student t test, Welch t
test, or Mann-Whitney test (continuous variables) and χ2 test
(categorical variables), as appropriate. In case of multiple group
comparisons, ANOVA followed by the Dunnett post hoc, Welch
and Dunnett T3 post hoc or Kruskal-Wallis and Dunn post hoc
tests were applied, as appropriate. For the statistical models‚
including multiple factors (eg, genotype, age, or treatment),
2-way ANOVA was used. In case of serial measurements,
as in dnPI3K and WT mice treated with hydroxychloroquine
(HCQ) or dobutamine, Greenhouse-Geisser–corrected 2-way
repeated-measures ANOVA was applied. Whenever significant, the main effects of these factorial designs were reported
on top of the respective panel. And, in general, this was followed by pairwise comparisons among different levels of a
given factor. Data distribution was tested for normality using
the Shapiro-Wilk test and depending on data distribution homogeneity of variances was verified using the Levene or BrownForsythe tests. Data violating these linear model assumptions
were either transformed or the abovementioned nonparametric
alternatives were used. Statistical analysis of survival data was
detailed in the Supplemental Methods. A 2-sided P value of
0.05 was considered significant. GraphPad Prism 9 (GraphPad
Software, LLC) or IBM SPSS statistics software (Version 25)
were used to run the analysis.

RESULTS
Cardiac Overexpression of IGF1 Receptor
Promotes Cardiac Health in Early Adulthood,
But Causes Heart Failure and Premature
Mortality Late in Life
To determine the long-term effect of activated IGF1R
signaling on the heart, we used male mice overexpressing the human IGF1R specifically in cardiac myocytes
(IGF1Rtg).10 We focused on male mice because the controversial effect of IGF1R signaling mainly concerns
males.3 Both IGF1Rtg mice and their WT littermates were
subjected to a lifelong follow-up of survival, and cardiac
structure and function, as well. To this end, a full cardiac workup composed of echocardiography, exercise

Circulation. 2022;145:1853–1866. DOI: 10.1161/CIRCULATIONAHA.122.059863

June 21/28, 2022 1855

ORIGINAL RESEARCH
ARTICLE

from the corresponding authors to other researchers for purposes of reproducing the results or replicating the procedure.

Biphasic Effects of Cardiac IGF1R Signaling

ORIGINAL RESEARCH
ARTICLE

Abdellatif et al

Biphasic Effects of Cardiac IGF1R Signaling

Downloaded from http://ahajournals.org by on September 9, 2022

tolerance testing, and cardiopulmonary capacity was
conducted at 3 physiologically relevant life stages; early
adulthood (3–6 months), midlife (12 months), and old
age (20 months; Figure 1A). It is not surprising10,17 that
IGF1Rtg mice exhibited pronounced cardiac hypertrophy
across the 3 life stages, as denoted by higher left ventricular (LV) mass normalized to body weight, posterior
wall thickness, and LV remodeling index (defined as the
ratio between LV mass and internal diastolic diameter)
than WT mice (Figure 1B–1E and Table S1). IGF1Rtg
hearts exhibited signs of hypertrophy also at the cardiomyocyte level (Figure S1A). IGF1Rtg and WT mice had
functionally similar heart rates, irrespective of age (Figure 1F). However, although IGF1Rtg mice showed superior cardiac contractility and better exercise capacity at
young age (Figure 1G and 1H), the beneficial effects of
IGF1R overexpression were lost by 12 months of age
(Figure 1G and 1H). Strikingly‚ we found that 20-monthold IGF1Rtg mice developed clear signs of cardiomyopathy characterized by increased LV fibrosis (Figure S1B),
reduced EF, lower cardiac output, and severe left atrial
remodeling (Figure 1G and 1I–1K) in the absence of LV
dilation (Table S1). These findings were further supported by invasive measures of cardiac function, including
maximal LV pressure, the maximum and minimum rates
of LV pressure change, and preload recruitable stroke
work, which were all significantly reduced in aged IGF1Rtg mice (Table S2). Evident systolic and diastolic dysfunctions in aged IGF1Rtg mice indicated an age-related
shift from physiological to pathological hypertrophy and
resembled human nondilated cardiomyopathy that is
commonly associated with hypertrophic remodeling.18
Consistent with this notion, exercise tolerance testing
coupled to indirect calorimetry revealed compromised
cardiopulmonary functional capacity in old IGF1Rtg mice
(Figure 1L) accompanied by pulmonary congestion, as
indicated by the increased tibia length–normalized lung
weight (Figure 1M). Taken together, these findings indicate that, although cardiac IGF1R overexpression promotes cardiac health during early adulthood, it exacerbates age-related cardiac decline, leading to increased
risk of heart failure with aging.
To determine whether age-associated cardiac decline
in IGF1Rtg mice reduces lifespan, we performed a longevity study which revealed that, despite exhibiting a
median survival comparable to WT mice (Figure 1N
and Table S3), IGF1Rtg mice had an obvious reduction
in maximum lifespan (Figure 1O). We then evaluated
various tissues by gross necropsy, which unveiled that
shorter maximum survival in these mice cannot be attributed to increased tumorigenesis (Figure 1P). Although
we acknowledge that determining the exact cause of
death in mice is extremely challenging, this finding, along
with the cardiac-specific nature of these mutants, might
suggest that reduced longevity in IGF1Rtg mice is driven
by cardiac insufficiency.
1856 June 21/28, 2022

Aged IGF1Rtg Mice Develop Heart Failure
Attributable to Reduced Autophagic Activity and
Mitochondrial Oxidative Capacity
We next sought to evaluate age-dependent changes of
IGF1R signaling by measuring circulating and cardiac
concentrations of IGF1 and assessing downstream effectors of the IGF1R pathway. IGF1Rtg mice exhibited
comparable plasma IGF1 concentrations, but significantly
lower cardiac IGF1 levels than their WT littermates, perhaps due to receptor-mediated internalization (Figure
S2). Regardless, higher cardiomyocyte IGF1R expression
significantly increased the pathway signaling activity, as
indicated by increased phosphorylation of the serine/threonine-protein kinase AKT at Ser473 and Thr308, both in
young and old IGF1Rtg mice (Figure 2A–2D). Old WT mice
also showed a significant, albeit slight, age-dependent increase in IGF1R expression, which did not appear to result
in a significant activation of AKT, at least up to the age
of 20 months (Figure 2A–2D). IGF1R stimulates protein
synthesis and suppresses catabolic pathways, such as autophagy, through the mammalian target of rapamycin complex 1 (mTORC1).19 Therefore, we determined the extent
of mTORC1 activation in IGF1Rtg mice by examining the
phosphorylation of the mTORC1 subunit PRAS40 (proline-rich AKT1 substrate 1) and that of several mTORC1
substrates, including p70 S6K (p70 ribosomal S6 kinase
1), 4E-BP1 (eIF4E-binding protein 1), and ULK-1 (Unc51-like kinase-1). IGF1Rtg mice exhibited increased phosphorylation of p70 S6K, 4E-BP1, and PRAS40 compared
with nontransgenic controls, and this difference was particularly clear at old age (Figure S3). mTOR-dependent
ULK-1 phosphorylation was significantly higher only in old
IGF1Rtg mice (Figure S4). In the absence of differences
in AMPK-dependent phosphorylation of ULK1 (Ser317;
Figure S5), mTOR-dependent ULK1 (Ser757) phosphorylation might result in a more pronounced age-associated
autophagy decline in IGF1Rtg mice.
To test this hypothesis, we determined whether
reduced autophagic activity underlies the detrimental cardiac phenotype of old IGF1Rtg mice, especially
because autophagy is indispensable for cardiac homeostasis in aging.20,21 To this end, we evaluated autophagy
markers in IGF1Rtg hearts that displayed a higher accumulation of the autophagic substrate p62 as early as at
12 months of age (Figure 2E and 2F). We also detected
higher levels of the autophagy-related lipidated form of
microtubule-associated protein 1A/1B-light chain 3B
(LC3B-II) in IGF1Rtg hearts (Figure 2G and 2H) that
could reflect either increased formation or reduced degradation of autophagosomes. To determine autophagic
flux in vivo, we injected IGF1Rtg and WT mice with the
protease inhibitor leupeptin (or saline) intraperitoneally,
and measured LC3B-II.22 Unlike WT controls, 12-monthold IGF1Rtg mice failed to further increase LC3-II in
response to leupeptin (Figure 2G and 2H), indicating
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Figure 1. Cardiac overexpression of IGF1R improves ejection fraction and effort tolerance in early adulthood, but causes heart
failure and premature mortality late in life.
A, Male mice with cardiomyocyte-specific overexpression of the human IGF1 receptor (IGF1Rtg) and their wild-type (WT) littermates (FVB/N
background) were subjected to a comprehensive assessment of cardiac function and structure at the indicated age. B, Representative
echocardiography-derived left ventricular (LV) M-mode tracings; C, LV mass normalized to body weight (BW); D, LV posterior wall thickness
(LVPW); E, LV remodeling index (LVRI); F, heart rate (HR); and G, LV ejection fraction (LVEF) in 6-, 12-, and 20-month-old IGF1Rtg and WT mice
(n=10 mice per group). H, Maximum workload during exercise tolerance testing in 3-, 12-, and 20-month-old IGF1Rtg and WT mice (n=5–6 mice
per group). I, Body surface area–normalized cardiac output (cardiac index), derived by echocardiography, in IGF1Rtg and WT mice at the age of 6,
12, and 20 months (n=10 mice per group). J and K, Representative heart photomicrographs (J) and body surface area–normalized left atrial area
(LAAi; K) in 20-month-old IGF1Rtg and WT mice (n=10 mice per group). L, Maximum oxygen consumption (Vo2max) during exercise tolerance
testing in IGF1Rtg and WT mice at the age of 3, 12, and 20 months (n=5–6 mice per group). (Continued )
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Figure 1 Continued. M, Lung weight normalized to tibia length (TL) in 20-month-old IGF1Rtg and WT mice (n=10 mice per group). N, KaplanMeier survival analysis of IGF1Rtg and WT mice (n=48/90 mice per group, respectively). Median survival is depicted by the dashed lines (please
see also Table S3 for details). O, Maximum lifespan calculated as the average lifespan of the longest-lived decile in IGF1Rtg and WT mice (n=5/9
mice per group, respectively). P, Tumor incidence detected by gross necropsy in IGF1Rtg and WT mice (20/17 mice per group, respectively).
Number in brackets indicates the number of mice that developed tumors. Indicated P values on top of panels (C–I and L) represent factor
comparisons by 2-way ANOVA including genotype and age as fixed factors, followed by simple main effects analysis of pairwise comparisons
between IGF1Rtg and their age-matched WT controls. Other P values were calculated by the Welch t test (K, M, and O) or χ2 test (P). Bars and
error bars show means and SEM, respectively, with individual data points superimposed. IGF1 indicates insulin-like growth factor 1; IGF1R, IGF1
receptor; and IGF1Rtg mice, mice overexpressing human IGF1R specifically in cardiomyocytes.
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that higher LC3-II levels at baseline result from blocked
autophagic flux. These results collectively suggest that
reduced cardiac autophagic flux precedes the development of an adverse cardiac phenotype in IGF1Rtg mice.
Because dysregulated autophagy is intimately linked
to aberrant function of cellular organelles, including mitochondria,20,21 we speculated that aged IGF1Rtg hearts
might be failing because of compromised mitochondrial
function. To test this, we evaluated both respiratory function and ATP production capacity in mitochondria isolated
from aged IGF1Rtg and WT hearts. Cardiac IGF1Rtg and
WT mitochondria surprisingly had comparable respiratory
capacity (Figure 2I). However, simultaneous measurement
of ATP kinetics revealed uncoupled oxidative phosphorylation from ATP synthesis because IGF1Rtg mitochondria
generated significantly lower amounts of ATP than WT
mice (Figure 2J), implying impaired mitochondrial oxidative
capacity and likely increased oxidative stress. In support of
this notion, targeted metabolome analysis of aged IGF1Rtg
hearts unveiled reduced levels of the tricarboxylic acid cycle
intermediates, fumarate and malate, and reduced antioxidative potential, as measured by NADPH/NADP ratio
(Figure 2K). Furthermore, we detected increased accumulation of the glycolytic intermediates, glucose 6-phosphate
and glycerol 3-phosphate, that, in conjunction with lactate
accumulation in IGF1Rtg myocardium (Figure S6), suggested increased anaerobic metabolism and glucose use
for energy production. Hence, mitochondrial disturbance
of IGF1Rtg hearts reduced oxidative phosphorylation and
stress resistance, both of which might contribute to the
pathogenesis of premature heart failure.
To establish a causal link between dysregulated autophagy and impaired cardiac function in old IGF1Rtgmice, we
supplemented a subset of mice with spermidine that we
have previously shown to enhance cardiac autophagy in
aged mice.14 We confirmed that spermidine effectively prevents IGF1-induced suppression of autophagy in cardiac
H9c2 cells (Figure 3A and 3B). After 5 months of spermidine feeding (3 mmol/L in the drinking water), IGF1Rtg mice
were subjected to an extensive in vivo cardiac assessment
(Figure 3C). Spermidine-fed IGF1Rtgmice exhibited heart
rates, LV mass, and remodeling indices that were comparable to untreated IGF1Rtg mice (Figure 3D–3F). Although
spermidine failed to reverse established cardiac hypertrophy, it ameliorated LV EF, left atrial remodeling, maximal
LV pressure, and the maximum and minimum rates of LV
pressure change, as well (Figure 3G–3K and Table S2).
1858 June 21/28, 2022

Preload recruitable stroke work, the gold standard measure of cardiac contractility, was also significantly higher
in spermidine-treated than in nontreated IGF1Rtg mice
(Figure 3L). Spermidine supplementation also improved,
at least in part, the levels of tricarboxylic acid cycle and
glycolytic intermediates in aged IGF1Rtg mice (Figure S7).
In aggregate, these results suggest that reduced cardiac
autophagy might be involved in accentuated cardiac dysfunction of aged IGF1Rtg mice.

Lower IGF1R Signaling Attributable to Reduced
PI3K Activity Extends Cardiac Healthspan at the
Expense of Cardiac Growth
To gain further insight into the role of cardiac IGF1R signaling in early versus late life stages, we performed a second
long-term study on mice with reduced IGF1R signaling.
Because IGF1R deletion might cause embryonic defects
and compromised perinatal survival,23,24 we instead used a
mouse model harboring an inactivated (dominant negative,
dn) p110α isoform of PI3K,13 which is a key IGF1R downstream effector (Figure 4A). Compared with WT controls,
cardiomyocyte-specific dnPI3K mice had a lower cardiac
IGF1 concentration (Figure S2) and clearly reduced IGF1R signaling, as evidenced by decreased phosphorylation
of AKT at Ser473 and Thr308 (Figure 4B and 4C).
Accordingly, dnPI3K mice exhibited lower body
weight–normalized LV mass, posterior wall thickness,
and remodeling index than WT mice at both 3 and 20
months of age (Figure 4D–4F). However, functional cardiac assessment revealed that young dnPI3K mice had
slightly, but significantly lower EF than WT mice both at
baseline and in response to β-adrenergic stimulation
(Figure 4G), indicating that young dnPI3K mice might
have suppressed cardiac growth, not attenuated remodeling. By contrast, aged dnPI3K mice had a significantly
higher EF than WT mice, thereby exhibiting a conspicuously lower age-dependent decline in EF (2-way ANOVA
interaction P=0.005; Table S4). Likewise, young, but not
old, dnPI3K mice exhibited lower exercise capacity than
WT controls (Figure S8). In fact, β-adrenergic stimulation
revealed that aged dnPI3K mice display a significantly
higher cardiac reserve capacity than aged WT mice (Figure 4G). These findings were further corroborated by
invasive measurements of cardiac performance, including maximal LV pressure, the maximum and minimum
rates of LV pressure change, and preload recruitable
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Figure 2. Impaired autophagy and mitochondrial oxidative capacity underlie the detrimental effect of cardiac IGF1R signaling in
aged IGF1Rtg mice.
A through D, Representative Western blots (A) and quantification (B) of cardiac IGF1 receptor (IGF1R) expression normalized to GAPDH,
and AKT phosphorylation at Ser473 (C) and Thr308 normalized to total AKT expression (D) in 6-month-old (young) and 20-month-old (old)
IGF1Rtg and WT mice (n=3–6 mice per group). E and F, Representative Western blots (E) and quantification of (F) the autophagy substrate p62
normalized to GAPDH in cardiac lysates of 12-month-old IGF1Rtg and WT mice (n=11/10 mice per group, respectively). G and H, Representative
Western blots (G) and quantification of (H) the lipidated form of the autophagy marker LC3-II in the hearts of 12-month-old IGF1Rtg and WT mice
that were treated with the protease inhibitor leupeptin (n=14/21 mice per group, respectively) or saline (n=8 mice per group). I and J, Paired
assessment of oxygen consumption rate (I) and corresponding ATP production (J) in cardiac mitochondria isolated from 20-month-old IGF1Rtg
and WT mice (n=4 mice per group). K, Relative difference in the tricarboxylic acid cycle intermediates, fumarate and malate, and the ratio between
reduced and oxidized forms of the cofactor nicotinamide adenine dinucleotide phosphate (NADPH/NADP) in young (3 months old) and old (20
months old) IGF1Rtg and WT mice (n=7–10 mice per group). Indicated P values on top of panels (B–D and H) represent factor comparisons
by 2-way ANOVA including genotype and age (B–D) or genotype and treatment (H) as fixed factors; the following simple main effects denote
pairwise comparisons between IGF1Rtg and their respective WT controls within a specific age or treatment. Other P values were calculated by
unpaired Welch t test or Mann-Whitney test (F and K) or paired Student t test (I and J). Bars and error bars show means and SEM, respectively,
with individual data points superimposed. FC indicates fold change; IGF1, insulin-like growth factor 1; IGF1R, IGF1 receptor; IGF1Rtg mice, mice
overexpressing human IGF1R specifically in cardiomyocytes; and WT, wild-type.

stroke work, which were all significantly ameliorated in
aged dnPI3K mice (Figure 4H–4K), albeit without any
change in left atrial area or lung weight (Figure S9). Thus,
despite delayed cardiac growth early in life, partial inhibition of IGF1R signaling induced cardioprotective effects
during aging. As a result, aged dnPI3K mice had a longer maximum lifespan than WT mice, with no apparent

difference in tumor incidence (Figure 4L–4N). Although
dnPI3K mice exhibited extended longevity compared
with IGF1Rtg animals (18.5% longer maximum lifespan,
P<0.001), they exhibited a higher risk of mortality at a
young age (Figure 4O). These data collectively corroborate the essential role of cardiac IGF1R signaling in early
life and its detrimental role in aging.
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Figure 3. The autophagy inducer spermidine ameliorates the cardiac phenotype of aged IGF1Rtg mice.
A and B, Representative confocal images (A) and quantification (B) of autophagic activity assessed by GFP-LC3 positive dots in GFP-LC3–
expressing H9c2 cells treated with increasing concentrations of IGF1 in the presence or absence of spermidine (6.25 µmol/L) for 6 hours. Scale
bar, 10 µm (n=4 biological replicates per condition). C, Schematic representation of spermidine (SPD) feeding protocol to male IGF1Rtg mice.
SPD (3 mmol/L) was added to the drinking water starting at the age of 15 months, and after 5 months cardiac parameters were assessed. D
through H, Echocardiography-derived (D) heart rate (HR), LV mass normalized to body weight (BW; E), LV remodeling index (LVRI; F), LV ejection
fraction (LVEF; G), and body surface area–normalized left atrial area (LAAi; H) in 20-month-old spermidine-treated and control IGF1Rtg and
WT mice (n=15/7/11 mice per group, respectively). I through L, Invasively measured left ventricular maximum pressure (Pmax; I), maximum rate
of pressure rise (dP/dtmax; J), maximum rate of pressure decay (–dP/dtmin; K), and preload recruitable stroke work (PRSW; L) in 20-month-old
spermidine-treated and control IGF1Rtg and WT mice (n=7/7/10 mice per group, respectively). Indicated P values on top of B represent factor
comparisons by 2-way ANOVA including IGF1 concentration and spermidine treatment as fixed factors. Other P values were calculated by
ANOVA with the Dunnett post hoc test. Bars and error bars show means and SEM, respectively, with individual data points superimposed. GFPLC3 indicates Green Fluorescent Protein-Microtubule-associated Protein 1A/1B-Light Chain 3; IGF1, insulin-like growth factor 1; IGF1R, IGF1
receptor; IGF1Rtg mice, mice overexpressing human IGF1R specifically in cardiomyocytes; LV, left ventricular; and WT, wild-type.

Considering that reduced autophagy contributed to
exacerbated cardiac aging in IGF1Rtg mice, we sought
to determine whether autophagy is also implicated in the
extended cardiac healthspan of dnPI3K mice. We measured cardiac expression of the autophagy marker LC3-II
in dnPI3K and WT mice that received an intraperitoneal
1860 June 21/28, 2022

injection of leupeptin or saline. Compared with saline
administration, leupeptin induced significantly higher
LC3-II accumulation in dnPI3K than WT hearts (Figure
S10A and S10B), indicating higher autophagic activity. To
determine whether increased autophagy inversely correlates with mTORC1 activity in dnPI3K mice, we analyzed
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Figure 4. Reduced cardiomyocyte IGF1R signaling in dnPI3K mice delays cardiac growth, but protects from age-related decline
in cardiac function.
A, Dominant negative PI3K (dnPI3K) male mice with reduced cardiomyocyte-specific IGF1R signaling and their WT littermates (FVB/N
background) were subjected to a comprehensive assessment of cardiac function and structure at the age of 3 months (young) and 20 months
(old). B and C, Representative Western blots (B) and quantification of (C) cardiac AKT phosphorylation at Ser473 and Thr308 normalized to total
AKT expression in 10-month-old dnPI3K and WT mice (n=5 mice per group). D through F, Echocardiographic assessment of left ventricular (LV)
mass normalized to body weight (BW; D), LV posterior wall thickness (LVPW; E), (Continued )
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Figure 4 Continued. and LV remodeling index (LVRI; F) in young and old dnPI3K and WT mice (n=10 young and 12–15 old mice per
genotype). G, LV ejection fraction (LVEF) before and after β-adrenergic stimulation by intraperitoneal injection of dobutamine (1.5 mg/kg IP)
in young (Left) and old (Right) dnPI3K and WT mice (n=5 young and n=10 old mice per genotype). H through K, Invasive assessment of LV
maximum pressure (Pmax; H), maximum rate of pressure rise (dP/dtmax; I), maximum rate of pressure decay (dP/dtmin; J), and preload recruitable
stroke work (PRSW; K) in young and old dnPI3K and WT mice (n=5–8 mice per group). L, Maximum lifespan was calculated as the average
lifespan of the longest-lived decile in dnPI3K and WT mice (n=8/9 mice per genotype, respectively). M, Kaplan-Meier survival analysis in dnPI3K
and WT mice (n=80/90 mice per genotype, respectively). The same WT control group as in Figure 1N was used. Median survival is indicated
by the corresponding dashed lines (also see Table S3 for further details). N, Tumor incidence detected by gross necropsy in dnPI3K and WT
mice (26/11 mice per genotype, respectively). Number in brackets indicates the number of mice that developed tumors. O, Daily mortality risk
in dnPI3K compared with IGF1Rtg mice (n=80/48 mice per genotype, respectively). P, Cardiac abundance of ATP/ADP ratio in 20-month-old
dnPI3K and WT mice (n=4–5 mice per genotype). Q, Relative difference in the tricarboxylic acid cycle intermediates, fumarate and malate,
and the ratio between reduced and oxidized forms of the cofactor nicotinamide adenine dinucleotide phosphate (NADPH/NADP) in young
(3 months old) and old (20 months old) dnPI3K and WT mice (n=5–9 mice per group). Indicated P values on top of D through K represent
factor comparisons by 2-way ANOVA including genotype and age as fixed factors (D–F, H–K) or genotype and dobutamine (G), followed by
simple main effects analysis of pairwise comparisons between dnPI3K and their age- or treatment-matched WT controls. Other P values were
calculated by the Welch t test or Mann-Whitney test, as appropriate (L, P through Q) or χ2 test (N). Bars and error bars show means and SEM,
respectively, with individual data points superimposed. dnPI3K indicates mice harboring an inactivated (dominant negative, dn) p110α isoform of
phosphoinositide 3-kinase; IGF1, insulin-like growth factor 1; IGF1R, IGF1 receptor; IGF1Rtg mice, mice overexpressing human IGF1R specifically
in cardiomyocytes; and WT, wild-type.
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several mTORC1 substrates. We found reduced phosphorylation of 4E-BP1 in dnPI3K mice (Figure S11). However, mTORC1 regulation appeared complex in dnPI3K
mice as 4E-BP1 expression was increased, whereas both
ULK1 (Ser757) phosphorylation and p70 S6K were not
altered (Figure S11). Also, AMPK (AMP-activated protein
kinase) expression and related ULK1 (Ser317) phosphorylation were not affected (Figure S12), suggesting
that ULK1 phosphorylation is not involved in autophagy
activation in dnPI3K mice. The TFEB (transcription factor EB) is another mTORC1 substrate that is intimately
linked to lysosome biogenesis and autophagy,25 but has
different phosphorylation kinetics from other mTORC1
substrates.26 TFEB phosphorylation by mTORC1 reduces
the electrophoretic mobility of TFEB,27,28 resulting in an
upward shift in the immunoblot signal (Figure S13A).
dnPI3K mice exhibited a higher TFEB signal at the lower,
unphosphorylated molecular weight (Figure S13A), suggesting reduced phosphorylation by mTORC1. Accordingly, in dnPI3K mice, TFEB target genes related to
lysosome biogenesis were upregulated (Figure S13A),29
suggesting enhanced TFEB activity.
To examine whether a cause-effect relationship exists
between increased autophagy and cardiac health in aged
dnPI3K mice, 19-month-old transgenic mice and their WT
littermates received daily intraperitoneal injections of HCQ
(60 mg/kg) to chronically inhibit autophagy in vivo (Figure
S10C).15 After 4 weeks of HCQ treatment, no significant
alteration was detectable in the body weight–normalized
LV mass of WT or dnPI3K mice (Figure S10D). However,
the difference in cardiac function between WT and dnPI3K
animals was entirely abolished after HCQ treatment. Before
HCQ treatment, aged dnPI3K mice exhibited a significantly improved Doppler-derived myocardial performance
index that is a global measure of LV function (best known
as Tei index; Figure S10E). Aged dnPI3K animals also had
a higher EF than WT mice, despite comparable heart rates
(Figure S10F and S10G). However, after 4 weeks of HCQ
administration, dnPI3K and WT mice had almost identical
1862 June 21/28, 2022

Tei indices and EF (Figure S10E and S10F), indicating
that a functional autophagic flux is required for improved
cardiac function in aged dnPI3K mice. Aged dnPI3K mice
also exhibited a higher cardiac ATP/ADP ratio that was
coupled to partial restoration of tricarboxylic acid cycle
metabolites and NADPH/NADP ratio (Figure 4P and 4Q)
without noticeable changes in glycolytic intermediates (Figure S14) compared with WT controls. Hence, these data
suggest that aged dnPI3K hearts exhibit improved cardiac
bioenergetics and mitochondrial metabolism in association
with enhanced autophagy.

Human Failing Hearts Exhibit Exaggerated
IGF1R Expression and Signaling Activity
Last, we examined the translational potential of our findings by evaluating the expression and signaling activity
of IGF1R and its downstream effectors in aged human
hearts with equivalent age to 20-month-old mice.30 We
used LV biopsies obtained from explanted failing hearts
and compared them with biopsies from control donors
who had echocardiographic evidence of preserved cardiac function in the presence or absence of LV hypertrophy (Table S5). Of note, there was no increase in IGF1R
expression in hypertrophic compared with control hearts
(Figure 5A and 5B). Downstream to IGF1R, there were
also no differences in the phosphorylation or expression
levels of AKT, ULK-1, and S6K in hypertrophic compared
with control hearts (Figure 5C–5H). In sharp contrast,
IGF1R expression increased by almost 2-fold in failing
compared with normal controls or nonfailing hypertrophic
human myocardia (Figure 5A and 5B). Consistently, and
in line with the results obtained from IGF1Rtg mice, failing
hearts exhibited increased phosphorylation of AKT (Figure 5C and 5D). Compared with controls, failing hearts
also exhibited elevated ULK-1 phosphorylation, perhaps
reflecting increased mTORC1 activity (Figure 5E and
5F). However, the phosphorylation and expression of
S6K were comparable among the groups (Figure 5G and
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Figure 5. Increased IGF1R signaling in human failing hearts.
Representative Western blots (A) and immunoblot analysis of cardiac IGF1 receptor (IGF1R) expression (B), AKT phosphorylation at Thr308
normalized to total AKT expression (C), AKT expression (D), ULK-1 phosphorylation normalized to total ULK-1 expression (E), ULK-1 expression
(F), S6K phosphorylation normalized to total S6K expression (G), and S6K expression (H) in left ventricular samples obtained from failing and
nonfailing human hearts with or without echocardiographic evidence of hypertrophy (n=9/10/10 hearts in Control, Hypertrophy, and Heart
Failure, respectively). GAPDH was used as a loading control. Indicated P values were calculated by Welch test with Dunnett T3 post hoc (B
and E), ANOVA with Tukey post hoc (C, D, F, G) or Kruskal-Wallis-test with Dunn post hoc (H). Bars and error bars show means and SEM,
respectively, with individual data points superimposed. FC indicates fold change; IGF1, insulin-like growth factor 1; IGF1R, IGF1 receptor; and
IGF1Rtg mice, mice overexpressing human IGF1R specifically in cardiomyocytes.

5H). In sum, these results indicate that heart failure is
associated with exaggerated IGF1R signaling in humans.

DISCUSSION
The combination of experimental and clinical evidence
provided in this study consistently suggests that the relationship between IGF1R signaling and cardiac function
is not linear, but rather biphasic and age-dependent (Figure 6), thereby bringing into question the current assertion
that IGF1R-PI3K signaling is inherently cardioprotective.

IGF1R signaling proved most crucial for cardiac structure
and function during early life, because young mice exhibited cardiac benefits in association with increased IGF1R
signaling. By contrast, attenuated cardiac growth and impaired heart function were evident in young dnPI3K mice
with reduced IGF1R signaling. It is striking, however, that
old dnPI3K mice showed a rejuvenated cardiac phenotype,
whereas old IGF1Rtg mice manifested accelerated cardiac
aging and signs of heart failure, suggesting that IGF1RPI3K signaling is deleterious for the aging heart. Conversely, cardiac-specific inactivation of PI3K p110α was
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Figure 6. Graphical summary of
the role of cardiomyocyte IGF1R
signaling in regulating cardiac health
during the course of life.
IGF1R signaling proved crucial for cardiac
homeostasis during early life as young
IGF1Rtg mice exhibited cardiac benefits
in association with increased IGF1R
signaling, whereas IGF1R activity was
deleterious for cardiac function in aged
IGF1Rtg mice. Conversely, reduced cardiac
IGF1R signaling in dnPI3K mice was
associated with lower cardiac performance
and increased risk of mortality in early
life, but extended cardiac healthspan and
maximum longevity later in life. dnPI3K
indicates mice harboring an inactivated
(dominant negative, dn) p110α isoform
of phosphoinositide 3-kinase; IGF1,
insulin-like growth factor 1; IGF1R,
IGF1 receptor; and IGF1Rtg mice, mice
overexpressing human IGF1R specifically
in cardiomyocytes.
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associated with an extension in maximum longevity, despite an increased risk of mortality in early life. These
findings echo a similar survival advantage described for
male mice with partial global deactivation of PI3K,31 yet
clarify that heart-specific modulation of the IGF1R-PI3K
pathway suffices to affect organismal lifespan.
IGF1R signaling mechanistically controls cellular growth
and metabolism through a wide network of downstream
pathways.1 Among these, autophagy, a catabolic pathway
essential for protein and organelle quality control, emerged
as a major determinant of the cardiac response to IGF1R
modulation. At young age, it appears that IGF1R signaling
promotes growth by favoring anabolic over catabolic reactions, leading to improved cardiac performance. However,
this comes at the expense of insufficient cardiomyocyte
maintenance by autophagy, which progressively declines
with aging.20 Because cardiomyocytes are terminally differentiated cells, they cannot dilute dysfunctional organelles through cell divisions, which means that they are
particularly vulnerable to dysfunctional autophagy. Indeed,
the autophagy-inducer spermidine rescued aged IGF1Rtg
mice from heart failure. In contrast, reduced IGF1R signaling extended the cardiac healthspan of dnPI3K mice
in an autophagy-dependent manner. In line with these
observations, a growing body of evidence suggests that
efficient autophagy promotes healthy cardiac aging with
various autophagy-inducing interventions showing promising cardioprotective effects in aged mice.20,32 By contrast,
dysfunctional autophagy in aged IGF1Rtg mice was associated with impaired mitochondrial function and oxidative
metabolism, leading to inefficient cardiac bioenergetics
and heart failure. Although a direct link between reduced
mitochondrial oxidative metabolism and premature onset
of heart failure was recently established in a number of
studies using mice deficient in the mitochondrial pyruvate
1864 June 21/28, 2022

carrier,33,34 future studies will be required to determine
whether specific targeting of mitochondrial metabolism
can delay aging. At least in dnPI3K mice, reduced cardiac
decline in aging was coupled to improved cardiac oxidative metabolism and energy reserves. Along similar lines,
improved oxidative metabolism has been reported for adipose tissue–specific mutant mice with reduced insulin/
IGF1 signaling.35
On the basis of our findings, we propose that age
determines the cardiac effects of IGF1R signaling, which
is essential for early-life cardiac growth but detrimental
in late life. Thus, our study suggests that inhibition of
cardiac IGF1R signaling in late life is likely to suppress
the age-related deterioration of cardiac function and
increase lifespan. In support of this idea, a recent study
showed that late-life administration of IGF1R monoclonal antibody effectively promotes both cardiac health
and lifespan, at least in female mice.3 Current evidence in
humans also suggests a U-shape relationship between
IGF1 levels and mortality.36 Although low serum IGF1 levels have been previously linked to a higher risk of heart
failure,37 we found exaggerated IGF1R signaling activity
in LV samples of patients with end-stage nonischemic
heart failure. In line with our observation, a recent study
reported IGF1R overexpression, at least at the transcriptional level, in 2 other forms of cardiomyopathy, ie, ischemic heart disease and heart failure with preserved EF.38
Because causality cannot be inferred from these observational studies, whether increased IGF1R signaling in
the heart reflects maladaptive or compensatory mechanisms remains an open question.39 Hence, clinical evaluation of pharmacological IGF1R/PI3K inhibitors, which
are already used against cancer,40 is required to determine their potential to improve the prognosis of elderly
patients at risk of heart failure.

Circulation. 2022;145:1853–1866. DOI: 10.1161/CIRCULATIONAHA.122.059863

Abdellatif et al

Considering that the effect of IGF1R signaling is less
controversial in female than in male mice,3 this study
used only male mice as test subjects. However, future
studies should clarify whether the dual role of IGF1R
signaling is sex dependent. Because PI3K does not exclusively mediate IGF1R signaling, dnPI3K mice cannot
be viewed as the exact opposite of IGF1Rtg mice. Thus,
future long-term studies using a conditional IGF1R deletion model will be needed to corroborate the findings
obtained in dnPI3K mice. Furthermore, we acknowledge
that spermidine is a pleiotropic molecule that might affect cellular processes other than autophagy.41 Hence,
future studies using more specific autophagy-inducing
interventions (eg, overexpression of autophagy-related
transgenes) are warranted to determine the exact contribution of autophagy to the avoidance of cardiac aging.
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